Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Mostrar otras versiones (1)

CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchida, Connor A., Brandes, Nadav, Bueno, Raymund, Trinidad, Marena, Mazumder, Thomas, Yu, Bingfei, Hwang, Byungjin, Chang, Christopher, Liu, Jamin, Sun, Yang, Hopkins, Caitlin R., Parker, Kevin R., Qi, Yanyan, Hofman, Laura, Satpathy, Ansuman T., Stadtmauer, Edward A., Cate, Jamie H.D., Eyquem, Justin, Fraietta, Joseph A., June, Carl H., Chang, Howard Y., Ye, Chun Jimmie, Doudna, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664023/
https://www.ncbi.nlm.nih.gov/pubmed/37794590
http://dx.doi.org/10.1016/j.cell.2023.08.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664023/
https://www.ncbi.nlm.nih.gov/pubmed/37794590
http://dx.doi.org/10.1016/j.cell.2023.08.041

Ejemplares similares